Pure Global AI
ZVA · structured requirements

🇱🇻 Latvia medical device regulatory data

Explore the medical device requirements currently available for Latvia, organized by topic and linked to official sources.

43 facts25 dimensions9 official sourceslatest verification 2026-09-16

Advertising, claims & promotion

Which claims, audiences, channels, approvals, and restrictions apply?

Compare countries

Approval validity & renewal

What expires, what is retained periodically, and when must renewal start?

Compare countries

LATMED registration is maintained by an annual vigilance-fee payment

validity.latmed-listing-maintained-by-annual-payment
Fact-level verified
Statement

The agency examines the applications of manufacturers, packers and distributors and enters the information in the LATMED database within 10 days of receipt. If the persons registered under paragraphs 4, 28 and 29 do not cover the agency's costs for the vigilance system within the deadline set by the agency, the agency removes the information about that person from the LATMED database.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

No

Target Decision Retained

Yes

Conditions
  • The annual fee amounts are EUR 105.20 and EUR 201.90 (source res-lv-mk895, Annex rows 62.1 and 62.2).

Effective from 2023-08-23

Latvian source; translation: '31. The agency shall examine the applications referred to in paragraphs 28 and 29 of these Regulations and shall enter the relevant information in the LATMED database within 10 days after receipt thereof. If the persons referred to in paragraphs 4, 28 and 29 of these Regulations do not cover the costs referred to in paragraph 30 within the deadline set by the agency, the agency shall remove the relevant information about the particular person from the LATMED database.'

Notified-body certificates are valid for no more than five years

validity.notified-body-certificate-maximum-five-years
Fact-level verified
Statement

Certificates issued by notified bodies under Annexes IX, X and XI of Regulation (EU) 2017/745 are valid for the period they indicate, which must not exceed five years. On application by the manufacturer the validity may be extended for further periods, each not exceeding five years, on the basis of a re-assessment under the applicable conformity assessment procedures.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

No

Target Decision Retained

No

Conditions
  • A supplement to a certificate remains valid as long as the certificate it supplements is valid.
  • There is no separate Latvian approval with a validity period: the Latvian file is a notification and the Latvian registration is maintained by the annual payment (see validity.latmed-listing-maintained-by-annual-payment).

Effective from 2021-05-26

English source. A Commission proposal of 16 December 2025 would remove the five-year maximum certificate validity; it was pending when checked and is not reflected here.

Authority & regime

Which authority and binding regime govern this product, task, and date?

Compare countries

Health Inspectorate is the market surveillance authority for medical devices

authority.market-surveillance-health-inspectorate
Fact-level verified
Statement

The Health Inspectorate (Veselības inspekcija) acts as the market surveillance authority for medical devices under the Product and Service Safety Law, the Conformity Assessment Law and Regulation (EU) 2017/745. It controls the operation of devices and carries out inspections at manufacturing sites, retail outlets, and at importers, distributors and authorised representatives.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

No

Target Decision Retained

Yes

Conditions
  • The Inspectorate may suspend the placing on the market, distribution or use of a device it classifies as unsafe or dangerous (MK noteikumi Nr. 461 paragraph 19.10).
  • The Inspectorate may require the manufacturer, authorised representative, importer or distributor to provide all conformity information and documentation in Latvian or another language of its choice (MK noteikumi Nr. 461 paragraph 6).

Effective from 2023-08-23

Latvian source; translation: '19. The Inspectorate, in the procedure laid down in these Regulations: 19.1. as the market surveillance authority carries out market surveillance of medical devices in accordance with the Product and Service Safety Law, the law "On Conformity Assessment" and Regulation No. 2017/745;'

State Agency of Medicines (Zāļu valsts aģentūra) is the medical device competent authority

authority.medical-devices-competent-authority
Fact-level verified
Statement

The medical device competent authority in Latvia is the State Agency of Medicines (Zāļu valsts aģentūra, ZVA). Its device functions are to register medical devices manufactured in Latvia, to issue authorisations for placing specially supplied medical devices on the market, to carry out medical device vigilance, and to issue authorisations for clinical investigations of medical devices. The agency maintains the LATMED device register and runs the notification procedure.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

No

Target Decision Retained

Yes

Conditions
  • Market surveillance and control of devices in use is carried out by the Health Inspectorate (Veselības inspekcija), not by the agency (MK noteikumi Nr. 461 paragraph 19.1).
  • The agency is a state institution under the supervision of the Minister of Health, supervised through the Ministry of Health (MK noteikumi Nr. 537 paragraph 1).

Latvian source; translation: '4.7. registers medical devices manufactured in Latvia, issues authorisations for placing specially supplied medical devices on the market, and carries out medical device vigilance; 4.8. issues authorisations for the performance of clinical investigations of medical devices.' The registry label 'ZVA' is an abbreviation; the full legal name is Zāļu valsts aģentūra (State Agency of Medicines).

Change control

Does the event require internal documentation, notice, prior approval, transfer, or a new application?

Compare countries

Changes to registered information must be notified within 10 working days

change.latmed-information-changes-ten-working-days
Fact-level verified
Statement

Persons registered under paragraphs 28 and 29 of Cabinet Regulation No. 461 must inform the State Agency of Medicines within 10 working days of changes to the information they submitted. An authorised representative established in Latvia must inform the agency immediately of changes to its paragraph 4 information.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

Yes

Target Decision Retained

No

Conditions
  • Manufacturers established in Latvia must also notify cessation of placing on the market and cessation of production, and changes to the paragraph 33 information, within 10 working days (paragraph 34).

Effective from 2023-08-23

Latvian source; translation: '32. The persons referred to in paragraphs 28 and 29 of these Regulations shall, within 10 working days, inform the agency of changes to the information submitted under paragraphs 28 and 29 of these Regulations.'

Re-labelling or re-packaging requires 28 days' notice to the agency

change.relabelling-repackaging-requires-28-day-notice
Fact-level verified
Statement

A distributor carrying out any of the activities referred to in Article 16(2)(a) and (b) of Regulation (EU) 2017/745 must inform the State Agency of Medicines at least 28 days before making the newly labelled or re-packaged device available on the Latvian market, and on request submit to the agency a sample or mock-up of the newly labelled or re-packaged device, including any translated label and instructions for use. Within the same 28-day period the distributor must submit a notified-body certificate covering the type of device concerned and confirming that the distributor's quality management system meets Article 16(3).

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Premarket Review

Local Application Required

Yes

Target Decision Retained

Yes

Conditions
  • The duty attaches only where the distributor performs the activities in Article 16(2)(a) and (b) of Regulation (EU) 2017/745.

Effective from 2023-08-23

Latvian source; translation: '41.2. a distributor which carries out any of the activities referred to in points (a) and (b) of Article 16(2) of Regulation No. 2017/745 - at least 28 days before making the newly labelled or re-packaged medical device available on the Latvian market, to inform the agency of the intention to make available the newly labelled or re-packaged device and, upon request, to submit to the agency a sample or mock-up of the newly labelled or re-packaged device, including any translated label and instructions for use;' The source text contains a broken hyperlink fragment after '2017/745' which has been removed; the wording is otherwise verbatim.

Classification rules

What local class follows from which rules and decisive product facts?

Compare countries

Devices are divided into classes I, IIa, IIb and III under MDR Annex VIII

classification.four-risk-classes-annex-viii
Fact-level verified
Statement

Medical devices are divided into classes I, IIa, IIb and III according to their intended purpose and inherent risks, with classification carried out under Annex VIII of Regulation (EU) 2017/745. Latvian law applies those classes directly: the notification procedure is keyed to class IIa, IIb and III, and Latvian registration and vigilance fees are set by class.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

No

Target Decision Retained

Yes

Conditions
  • Disputes between manufacturer and notified body on the application of Annex VIII go to the competent authority of the Member State of the manufacturer's registered place of business (Article 51(2)).

Effective from 2021-05-26

English source. The Latvian notification thresholds (class IIa, IIb, III) in MK noteikumi Nr. 461 paragraph 9 confirm the classes are applied directly in Latvia.

Clinical investigation & performance

Which clinical or IVD performance evidence or study is required and accepted?

Compare countries

The agency issues authorisations for medical device clinical investigations

clinical.agency-authorises-clinical-investigations
Fact-level verified
Statement

The State Agency of Medicines issues authorisations for the performance of clinical investigations of medical devices; this is one of the device tasks assigned to the agency by its statute, alongside issuing authorisations for placing specially supplied medical devices on the market and carrying out medical device vigilance.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Premarket Review

Local Application Required

Yes

Target Decision Retained

Yes

Conditions
  • The substantive procedure for clinical investigations of devices intended for humans and performance studies of IVDs is set by the Cabinet under Article 34(2)(1) of the Medical Treatment Law (source res-lv-arstniecibas-likums).
  • Sponsors must insure their and the researcher's civil liability for harm to participants' health or life for the whole study period, under a separate contract concluded before the study begins (Article 34(4)-(6)).

Latvian source; translation: '4.8. issues authorisations for the performance of clinical investigations of medical devices;' The documentation examination fee for a clinical investigation or performance study is EUR 1500.00 and for substantial changes EUR 900.00 (source res-lv-mk895, Annex rows 55-57).

Device definition & scope

Is the product a device, IVD, accessory, software, or borderline product locally?

Compare countries

Latvian law defines a medical device by reference to MDR Article 2(1)

scope.device-definition-by-reference-to-mdr
Fact-level verified
Statement

Latvian law contains no autonomous medical device definition: Article 1 point 21 of the Medical Treatment Law defines a medical device as any instrument, apparatus, appliance, software, implant, reagent, material or other article that meets the definition in Article 2(1) of Regulation (EU) 2017/745. Cabinet Regulation No. 461 paragraph 5 repeats that reference and extends the national rules to accessories and products covered by Article 1(4) of the Regulation.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

No

Target Decision Retained

Yes

Conditions
  • Point 30 of the same Article defines an in vitro diagnostic medical device by reference to Article 2(2) of Regulation (EU) 2017/746.

Effective from 1997-10-01

Latvian source; translation: '21) medical devices - any instrument, apparatus, appliance, software, implant, reagent, material or other article which meets the definition referred to in Article 2(1) of Regulation (EU) No 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices ...'. The point was introduced by later amendment; 1997-10-01 is the law's general entry into force, not the date of this point.

Dossier requirements

Which evidence, local deltas, formats, and signatures are required?

Compare countries

The agency verifies the EU declaration of conformity and notified-body certificates

dossier.agency-verifies-eu-conformity-documents
Fact-level verified
Statement

In the notification procedure the State Agency of Medicines checks the EU declaration of conformity and the certificates issued by notified bodies for conformity with the national regulation, Regulation (EU) 2017/745 and directly applicable EU acts, and against the information stated in the notification form. Where the submitted information does not conform or documents are missing, the agency asks the applicant to submit corrections or supplements. The agency may require translations of the documents submitted.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

Yes

Target Decision Retained

Yes

Conditions
  • The agency's check leads to no approval decision; completion of the notification is marked by publication of the data (paragraph 11).
  • The dossier of the notification is limited to the notification form (Annex 1), the copy of the EU declaration of conformity and copies of the valid notified-body certificates (paragraph 9).

Effective from 2023-08-23

Latvian source; translation: '10. The agency shall check the conformity of the EC (EU) declarations of conformity of the medical device received in the notification procedure and of the certificates issued by notified bodies with the requirements of these Regulations, Regulation No. 2017/745 and directly applicable European Union legal acts adopted on its basis, as well as with the information stated in the notification form (Annex 1). Where non-conformity of the submitted information or a lack of documents is found, the agency shall inform the submitter thereof, requesting appropriate corrections or supplements.' The translation right is paragraph 16 ('The agency is entitled to request translations of the documents submitted in the notification procedure.').

Economic-operator roles

Which manufacturer, representative, holder, applicant, importer, and distributor roles apply?

Compare countries

Manufacturers outside the EU must designate a sole authorised representative

operator.sole-authorised-representative-required
Fact-level verified
Statement

A manufacturer of a device that is not established in a Member State may place the device on the Union market only if it designates a sole authorised representative. Where that authorised representative has registered a place of business in Latvia, it must give the State Agency of Medicines, before the device is placed on the market, its own name, registration number, legal address and unified registration number, the address of the registered place of business, the manufacturer's identity, the manufacturer's written mandate under Article 11(3) of Regulation (EU) 2017/745, and the UDI-DI of the manufacturer's class I devices and procedure packs intended for the EU/EEA market - and must notify changes immediately.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

Yes

Target Decision Retained

No

Conditions
  • The Union-level requirement to designate a sole authorised representative is Article 11(1) of Regulation (EU) 2017/745 (source res-lv-mdr); the Latvian paragraph 4 duty is an additional registration duty on representatives established in Latvia.
  • Authorised representatives of third-country manufacturers without an establishment anywhere in the EU/EEA are also recorded in the LATMED database (MK noteikumi Nr. 461 paragraph 20.3).

Effective from 2023-08-23

Latvian source; translation of the opening words: '4. If the authorised representative has registered a place of business in the Republic of Latvia, it shall, before placing the medical device on the market, provide the State Agency of Medicines (hereinafter - the agency) with the following information (and shall immediately inform of changes to this information): 4.1. name, registration number and legal address, as well as the unified registration number (if one has been assigned); 4.2. the address of the registered place of business; 4.3. the manufacturer in whose name the medical devices are placed on the market - name, registration number and legal address, as well as the unified registration number (if one has been assigned); 4.4. the manufacturer's written mandate referred to in Article 11(3) of Regulation No. 2017/745;'

A non-EU manufacturer may only place a device on the Union market through a sole authorised representative

operator.third-country-manufacturer-needs-union-representative
Fact-level verified
Statement

Under Regulation (EU) 2017/745, where the manufacturer of a device is not established in a Member State, the device may only be placed on the Union market if the manufacturer designates a sole authorised representative. This applies equally to an FDA-, PMDA-, MFDS- or NMPA-approved manufacturer: designating a representative does not replace CE marking.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

Yes

Target Decision Retained

No

Conditions
  • The representative's mandate must be accepted in writing and is defined by Article 11(2)-(3).
  • A representative established in Latvia has the additional national duty to file the paragraph 4 information with the State Agency of Medicines before the device is placed on the market.

Effective from 2021-05-26

English source. The closing sentence of the statement is the reading of the source combined with Article 5(1) and Article 52(1) of the same Regulation (no third-country approval is named anywhere in the Regulation).

Establishment, import & distribution

Which establishment licences, importer permissions, and distribution controls apply?

Compare countries

Devices may be distributed in Latvia only through distributors listed in LATMED

establishment.distributor-must-be-listed-in-latmed
Fact-level verified
Statement

Distributors referred to in paragraph 29 may make medical devices available on the Latvian market only if information about them as distributors is entered in the LATMED database. From 1 January 2026, manufacturers, importers and distributors may supply devices for distribution only where the distributors making the devices available are listed in LATMED.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

Yes

Target Decision Retained

No

Conditions
  • Both paragraphs were inserted by Cabinet Regulation No. 824 of 22 December 2025; the supply-chain paragraph 41.2 enters into force on 1 January 2026 (paragraph 117 of the regulation).

Effective from 2025-12-24

Latvian source; translation: '41.1 The distributors of medical devices referred to in paragraph 29 of these Regulations are entitled to make medical devices available on the market of the Republic of Latvia if information about the particular person as a distributor is entered in the LATMED database.'

Latvian importers must notify the Inspectorate and the agency of risky or falsified devices

establishment.importer-risk-notification
Fact-level verified
Statement

An importer operating in Latvia which considers, or has reason to consider, that a device it has imported and placed on the Latvian market presents a serious risk or is falsified must inform the Health Inspectorate and the State Agency of Medicines.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

No

Target Decision Retained

No

Conditions
  • The parallel duty for distributors is paragraph 41.1 of the same regulation.

Effective from 2023-08-23

Latvian source; translation: '42. If an importer carrying on business in the Republic of Latvia considers or has reason to consider that a medical device which it has imported and placed on the Latvian market presents a serious risk or is falsified, it shall inform the Inspectorate and the agency thereof.'

Latvian distributors must file an application with the agency before making devices available

establishment.latvian-distributor-registration
Fact-level verified
Statement

A distributor whose place of business is registered in Latvia and which makes medical devices available to healthcare institutions or healthcare professionals, or supplies them for distribution to other distributors, must file an application with the State Agency of Medicines before making the devices available. The application states the distributor's name, registration number, legal address, telephone and e-mail, and the classification class plus the manufacturer's name and legal address of the devices it intends to make available. The agency enters the information in the LATMED database within 10 days.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

Yes

Target Decision Retained

No

Conditions
  • The paragraph was narrowed by Cabinet Regulation No. 824 of 22 December 2025 (in force 24 December 2025): distributors serving only non-professional end users are no longer within the registration duty.
  • Registered persons cover the agency's vigilance-system costs by an annual payment; non-payment leads to removal of their information from LATMED (paragraphs 30 and 31).

Effective from 2025-12-24

Latvian source; translation: '29. Distributors of medical devices whose place of business is registered in the Republic of Latvia and which make medical devices available to healthcare institutions or healthcare persons or supply them for distribution to other distributors shall, before making the medical devices available, submit to the agency an application stating the information referred to in sub-paragraphs 28.1, 28.2, 28.3 and 28.5 of these Regulations, as well as the classification class, the manufacturer's name and legal address of the medical devices they intend to make available.'

Fees

What regulator fee applies to this class, route, event, and date?

Compare countries

ZVA device fees: annual vigilance fee, free-sale certificate, non-CE device assessment

fees.agency-device-fee-schedule
Fact-level verified
Statement

The State Agency of Medicines fee schedule (Cabinet Regulation No. 895 of 18 December 2024, in force 1 January 2025) fixes an annual medical device vigilance-system fee of EUR 105.20 for class I devices and other (remaining) and class A IVDs, and EUR 201.90 for class IIa, IIb and III devices, A-list, B-list and self-test, class B, C and D IVDs - payable per manufacturer, authorised representative or distributor. Issuing a medical device free-sale certificate costs EUR 185.41, and the examination of an application and documentation to place on the market individual devices that have not undergone conformity assessment and are not CE-marked costs EUR 528.60.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

No

Target Decision Retained

No

Conditions
  • If an undertaking distributes low-risk and medium- or high-risk devices together, only the single annual payment of EUR 201.90 is due, and the annual fee is fixed regardless of the range of devices, turnover or number of manufacturers.
  • The fees in the schedule are exclusive of VAT, which is not applied under section 3 of the Value Added Tax Law.
  • Fee amounts are due for re-verification after 12 months under the registry review policy.

Effective from 2025-01-01

Latvian source; the four rows are quoted from the Annex (pielikums) to Cabinet Regulation No. 895, whitespace-flattened from the original table. Row 54 = free-sale certificate; row 62 = annual medical device vigilance-system fee (62.1 low risk, 62.2 medium/high risk); row 63 = examination of an application and documentation for devices without conformity assessment and without CE marking.

Label, IFU & language

Which label and IFU elements, languages, symbols, and translation controls apply?

Compare countries

Information for users and patients must be in Latvian

label.state-language-required-for-device-information
Fact-level verified
Statement

Information for users and patients under Annex I section 23 of Regulation (EU) 2017/745 must be provided in the Latvian state language. That information and other device documentation may be in another language only where the device is intended for use solely in a healthcare institution and only by correspondingly qualified and trained healthcare persons, with the consent of that healthcare institution to the language used.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

No

Target Decision Retained

Yes

Conditions
  • The Health Inspectorate may require the manufacturer, authorised representative, importer or distributor to supply all conformity information and documentation in the state language or another suitable language of the Inspectorate's choice, and sets a 30-day deadline for translations of technical documentation unless a shorter deadline is justified by serious immediate risk.
  • For imported goods whose marking, instructions for use, warranty documents or technical passport are in a foreign language, a Latvian translation must be attached, and where a foreign language is used alongside Latvian the Latvian text must have the principal place and must not be smaller or narrower in form or content (ZVA guidance referencing the State Language Law).

Effective from 2023-08-23

Latvian source; translation: '6. The information for users and patients referred to in section 23 of Annex I to Regulation No. 2017/745 shall be provided in the state language. The information referred to in section 23 of Annex I to Regulation No. 2017/745 and other documentation of the medical device may be not in the state language only in cases where the medical device is intended for use only in a healthcare institution and may be used only by correspondingly qualified and trained healthcare persons, provided that the consent of the particular healthcare institution to the use of the particular language in the documentation of the medical device has been received.'

IVD information for users and patients must be in Latvian

label.state-language-required-for-ivd-information
Fact-level verified
Statement

Information for users and patients under Annex I section 20 of Regulation (EU) 2017/746 must be provided in the Latvian state language. It and other IVD documentation may be in another language only where the IVD is intended for use solely in a healthcare institution by correspondingly qualified and trained healthcare persons, with that institution's consent.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

No

Target Decision Retained

Yes

Conditions
  • The Health Inspectorate may require the conformity information and documentation in the state language or another language of its choice, with a 30-day deadline for technical documentation translations.

Effective from 2023-10-13

Latvian source; translation: '6. The information for users and patients set out in section 20 of Annex I to Regulation No. 2017/746 shall be provided in the state language. The information set out in section 20 of Annex I to Regulation No. 2017/746 and other documentation of the in vitro diagnostic medical device may be not in the state language if the in vitro diagnostic medical device is intended for use only in a healthcare institution and will be used only by correspondingly qualified and trained healthcare persons, provided that the consent of the particular healthcare institution to the use of the particular language in the documentation has been received.'

Manufacturer PMS

Which PMS plan, report, PMCF or PMPF, trend, and lifecycle-update duties apply?

Compare countries

Manufacturers must run a post-market surveillance system per device

pms.manufacturer-post-market-surveillance-system
Fact-level verified
Statement

For each device, manufacturers must plan, establish, document, implement, maintain and update a post-market surveillance system proportionate to the risk class and appropriate for the device type. That system must be an integral part of the manufacturer's quality management system referred to in Article 10(9), and must actively and systematically gather, record and analyse data on quality, performance and safety throughout the device's lifetime.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Postmarket Surveillance

Local Application Required

No

Target Decision Retained

No

Conditions
  • The Latvian regulation assigns the agency the task of carrying out medical device vigilance and the post-market and technical surveillance framework (MK noteikumi Nr. 461 paragraphs 1.5 and 18.5).

Effective from 2021-05-26

English source.

Official forms & portals

Which current form, portal, account, and submission package must be used?

Compare countries

LATMED is the Latvian medical device register, maintained by the agency

portal.latmed-database-maintained-by-agency
Fact-level verified
Statement

The State Agency of Medicines maintains the LATMED electronic database, the medical device register, and is the controller of the LATMED state information system. LATMED holds information on manufacturers of class I devices and procedure packers established in Latvia, on notified medical devices and their manufacturers and distributors, on authorised representatives of manufacturers with no establishment in any EU or EEA state, and on incidents connected with the use of medical devices.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

No

Target Decision Retained

No

Conditions
  • The notification form for medical devices is Annex 1 to Cabinet Regulation No. 461 (source res-lv-mk461); the IVD notification form is Annex 1 to Cabinet Regulation No. 582.

Effective from 2023-08-23

Latvian source; translation: '20. The agency shall maintain the LATMED database. The agency is the controller of the LATMED state information system within the meaning of the State Information Systems Law. The LATMED database shall store the following information: 20.1. information about manufacturers of class I medical devices and device packers referred to in Article 22(1) of Regulation No. 2017/745 whose place of business is registered in the Republic of Latvia; 20.2. information about notified medical devices, their manufacturers and distributors; 20.3. information about authorised representatives of manufacturers of medical devices which have no registered place of business in any EU or EEA Member State; 20.4. information about incidents connected with the use of medical devices;'

QMS, audit & inspection

Which QMS, audit, inspection, and certificate scope is accepted or required?

Compare countries

Manufacturers must maintain an MDR quality management system

qms.manufacturer-quality-management-system
Fact-level verified
Statement

Manufacturers of devices other than investigational devices must establish, document, implement, maintain, keep up to date and continually improve a quality management system ensuring compliance with Regulation (EU) 2017/745 in a manner proportionate to the risk class and device type. That system must be an integral part of the manufacturer's organisation for all processes, procedures and devices affecting quality.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

No

Target Decision Retained

Yes

Conditions
  • The QMS must also take account of changes in device design or characteristics and changes in harmonised standards or common specifications (Article 10(9), first sentence).
  • Under the transitional provisions, manufacturers of legacy devices had to have an Article 10(9) QMS in place by 26 May 2024 (source res-lv-r2023-607, Article 120(3c)(d)).

Effective from 2021-05-26

English source. On the Latvian side, the Health Inspectorate is entitled to check that the production process conforms to the device technical documentation and harmonised standards (MK noteikumi Nr. 461 paragraph 19.8).

Recall, FSCA & market surveillance

Which recall, FSCA, notice, and authority-coordination duties apply?

Compare countries

The Inspectorate may suspend placing on the market, distribution or use of a device

recall.inspectorate-suspension-powers
Fact-level verified
Statement

The Health Inspectorate may suspend the placing on the market, distribution or use of a device where it classifies the device as unsafe or dangerous and its further use endangers the health or life of a patient, user or third person. It may require the holder or keeper of a device to take corrective action to secure conformity, and may require corrective action where distribution or operation does not comply with the regulation or Regulation (EU) 2017/745.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Postmarket Surveillance

Local Application Required

No

Target Decision Retained

Yes

Conditions
  • Persons in paragraph 9 must immediately notify the agency of any action they take to suspend distribution or to request recall of devices, and of the reasons (paragraph 17.3).
  • Where CE marking has been used improperly or not at all, the Inspectorate informs the manufacturer or authorised representative, the notified body, the Commission and the other EU and EEA Member States (paragraph 63).

Effective from 2023-08-23

Latvian source; translation: '19.10. is entitled to suspend the placing on the market, distribution or use of the medical device concerned where the medical device is classified as unsafe or dangerous and its further use endangers the health or life of a patient, user or third person;'

Registration pathways

Which registration, notification, listing, reliance, or conformity route applies?

Compare countries

IVD notification procedure covers class B, C, D, A-list, B-list and self-test IVDs

pathway.ivd-notification-procedure
Fact-level verified
Statement

For in vitro diagnostic medical devices, the Latvian notification procedure applies to class B, C and D devices as well as to A-list, B-list and self-test IVDs: the notifier files the notification form (Annex 1 to Cabinet Regulation No. 582) with the State Agency of Medicines and attaches a copy of the EU declaration of conformity and copies of valid notified-body certificates.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

Yes

Target Decision Retained

No

Conditions
  • After the agency publishes the notified data, the notification procedure is deemed complete and the device may be placed on the Latvian market without an agency decision (paragraph 10 and 11 of the regulation).

Effective from 2023-10-13

Latvian source; translation: '8. Persons who in the territory of the Republic of Latvia start placing on the market class B, C and D, as well as A-list, B-list and self-test in vitro diagnostic medical devices, shall submit to the agency a completed notification form (Annex 1) and attach a copy of the EC (EU) declaration of conformity, as well as copies of valid certificates issued by notified bodies (hereinafter - the notification procedure).'

Notification procedure is the Latvian pre-market filing for class IIa, IIb and III devices

pathway.notification-procedure-class-iia-iib-iii
Fact-level verified
Statement

An economic operator who in Latvia starts placing on the market class IIa, IIb or III medical devices files a completed notification form (Annex 1 to the regulation) with the State Agency of Medicines, attaching a copy of the EU declaration of conformity and copies of the valid notified-body certificates. One notification covers the devices of one manufacturer contained in one certificate. The agency publishes the notification data within 10 working days and the procedure is then complete; the notifier may then place the device on the market without an agency decision.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

Yes

Target Decision Retained

No

Conditions
  • Class I devices that are not sterile and have no measuring function are outside the notification procedure.
  • The notification is not an approval: no agency decision or approval is issued (paragraph 12).
  • The procedure is not required where the manufacturer complies with MDR Article 29(4) EUDAMED registration, in the six-to-eighteen-month window after the Commission announces full EUDAMED functionality (paragraph 13).

Effective from 2023-08-23

Latvian source; translation: '9. Persons who in the territory of the Republic of Latvia start placing on the market class IIa, IIb and III medical devices shall submit to the agency a completed notification form (Annex 1) and attach a copy of the EC (EU) declaration of conformity, as well as copies of valid certificates issued by notified bodies (hereinafter - the notification procedure). One notification contains information about the medical devices of one manufacturer contained in one certificate.'

Reliance & recognition

Which foreign decisions or evidence can be reused, with what effect and conditions?

Compare countries

Existing records include acceptance, restrictions and evidence reuse. The applicable product scope and conditions are preserved below; a reference does not by itself confer market access.

Latvia approvals and evidence in other markets (0 records)

No linked record is currently maintained. This does not establish that a pathway is unavailable.

Prior approvals and evidence for Latvia (4 records)

LatviaUS FDA · Japan MHLW / PMDA · South Korea MFDS · NMPA

Prior approval / evidence record

No Latvian market-access route on the basis of an FDA, PMDA, MFDS or NMPA approval

reliance.no-foreign-approval-route
Fact-level verified
Statement

Latvia operates no abridged, fast-track or recognition pathway for a foreign device approval. A device holding only a US FDA, Japan PMDA, Korea MFDS or China NMPA approval cannot be placed on the Latvian market: the Latvian pre-market notification procedure (paziņošanas procedūra) requires a copy of the EU declaration of conformity and copies of valid notified-body certificates issued under Regulation (EU) 2017/745, and no Latvian or Union instrument names a third-country approval as a basis for market access.

Source Approval

none

Edge Type

No Reliance Route

Market Access Strength

none

Regulatory Layer

Premarket Review

Local Application Required

No

Target Decision Retained

Yes

Conditions
  • The only non-CE pre-market route in Latvian law is the exceptional national authorisation under MK noteikumi Nr. 461 paragraphs 35-38 (public health or patient safety need, no conforming alternative), which is assessed against MDR Annex I essential requirements, harmonised standards and test results, not against any foreign approval.
  • Class I devices that are not placed on the market sterile and have no measuring function are not subject to the paragraph 9 notification at all, but still require conformity with Regulation (EU) 2017/745 (source res-lv-mdr, Article 5(1) and Article 52(1)).
  • The notification route for in vitro diagnostic devices is the parallel procedure in MK noteikumi Nr. 582 paragraph 8 (source res-lv-mk582).

Effective from 2023-08-23

Latvian source; translation: '9. Persons who in the territory of the Republic of Latvia start placing on the market class IIa, IIb and III medical devices shall submit to the agency a completed notification form (Annex 1) and attach a copy of the EC (EU) declaration of conformity, as well as copies of valid certificates issued by notified bodies (hereinafter - the notification procedure).' The excerpt shows that the only Latvian pre-market procedure is conditioned on EU documentation, i.e. on CE marking; the Union-side rule that a device may be placed on the market only if it complies with the Regulation is evidenced by the separately declared source res-lv-mdr (Article 5(1), Article 52(1)). No Latvian or EU instrument consulted names FDA, PMDA, MFDS or NMPA approval as a market-access basis.

LatviaEU conformity assessment

Prior approval / evidence record

CE marking under the Union regulations is the domestic route; no separate Latvian approval decision

reliance.eu-ce-marking-is-the-domestic-route
Fact-level verified
Statement

A CE mark under Regulation (EU) 2017/745 (or 2017/746 for IVDs) is the domestic route into Latvia and is valid throughout the EU/EEA. Once the Latvian notification procedure is complete, the notifier is entitled to place the device on the Latvian market without any decision or approval of the State Agency of Medicines; the agency publishes the notification data and the procedure is then deemed complete. What remains are local obligations: a manufacturer without an EU establishment must designate a sole authorised representative, and a distributor established in Latvia must be entered in the LATMED database before making devices available.

Source Approval

EU CE Marking under Regulation (EU) 2017/745 (MDR) for medical devices and Regulation (EU) 2017/746 (IVDR) for in vitro diagnostic medical devices

Edge Type

Abridged Or Recognition Route

Market Access Strength

facilitated

Regulatory Layer

Premarket Review

Local Application Required

Yes

Target Decision Retained

No

Conditions
  • The notification attaches to class IIa, IIb and III medical devices (MK noteikumi Nr. 461 paragraph 9) and to class B, C and D, A-list, B-list and self-test IVDs (MK noteikumi Nr. 582 paragraph 8).
  • The agency checks the submitted declaration of conformity and notified-body certificates against the national regulation, Regulation (EU) 2017/745 and directly applicable EU acts, and may require corrections or translations (MK noteikumi Nr. 461 paragraphs 10 and 16).
  • Manufacturers not established in a Member State may place a device on the Union market only if they designate a sole authorised representative (source res-lv-mdr, Article 11(1)).
  • Distributors established in Latvia may make devices available on the Latvian market only if information about them is entered in the LATMED database (MK noteikumi Nr. 461 paragraph 41.1).
  • Notification may be omitted once the manufacturer complies with MDR Article 29(4) EUDAMED registration, in the window from six to eighteen months after the Commission announces full EUDAMED functionality (MK noteikumi Nr. 461 paragraph 13).

Effective from 2023-08-23

Latvian source; translation: '12. The persons referred to in paragraph 9 of these Regulations, after completion of the notification procedure, are entitled to place the medical device on the market of the Republic of Latvia without a decision or approval of the agency.' The excerpt supports the bounded claim that Latvia issues no separate national approval for a CE-marked device; the EU/EEA-wide validity of the CE mark rests on Regulation (EU) 2017/745 itself (source res-lv-mdr).

LatviaUS FDA

Prior approval / evidence record

FDA 510(k)/PMA

Authority

FDA 510(k)/PMA

Accepted

No

Benefit

No substitute for EU MDR conformity assessment; useful as predicate documentation in the technical file

EUR-Lex Regulation (EU) 2017/745 (MDR)Commission Implementing Regulation (EU) 2026/977, Art. 2 — maximum notified-body conformity assessment timelines (30 + 120/90 parallel + 20 days)Medicīnisko ierīču noteikumi (Cabinet Regulation No. 461 of 15.08.2023, in force 23.08.2023; current redaction in force from 01.01.2026) — § 9 the IIa/IIb/III notification, § 11 the ten-working-day publication, §§ 28, 29 and 41.1 the LATMED registration, § 31 the ten-day LATMED entry and §§ 70 and 74.1 the three-day signal reportsZāļu valsts aģentūra — Pirms laišanas apgrozībā: Brīvās tirdzniecības sertifikāta saņemšana — 'Brīvās tirdzniecības sertifikātu ZVA izsniedz 30 dienu laikā pēc iesnieguma un tam pievienoto dokumentu saņemšanas.'

Maintained reference · planning ranges remain estimates · reviewed 2026-09-16

LatviaEU conformity assessment · US FDA · Japan MHLW / PMDA · South Korea MFDS · NMPA

Prior approval / evidence record

MDR transitional periods benefit only holders of Directive 90/385/EEC or 93/42/EEC certificates

reliance.mdr-transitional-periods-only-for-mdd-aimdd-certificates
Fact-level verified
Statement

The extended MDR transitional periods run only for devices covered by a certificate issued under Directive 90/385/EEC or Directive 93/42/EEC, or whose pre-2021 declaration of conformity did not require a notified body. As at 15 September 2026 the extended dates are 31 December 2027 for all class III devices and class IIb implantable devices other than certain well-established technologies, and 31 December 2028 for other class IIb devices, class IIa devices and class I devices placed on the market sterile or with a measuring function. A US FDA, Japan PMDA, Korea MFDS or China NMPA approval confers no transitional benefit because it is not a Directive certificate.

Source Approval

none

Edge Type

No Reliance Route

Market Access Strength

none

Regulatory Layer

Premarket Review

Local Application Required

No

Target Decision Retained

Yes

Conditions
  • Benefiting devices must continue to comply with the applicable Directive, have no significant changes in design and intended purpose, present no unacceptable risk, and the manufacturer must have put in place an MDR Article 10(9) quality management system by 26 May 2024 and lodged a notified-body application with a written agreement signed by 26 September 2024 (Article 120(3c) as inserted by Regulation (EU) 2023/607).
  • Regulation (EU) 2023/607 also deleted the sell-off deadline, so devices lawfully placed on the market during the transitional period may continue to be made available.
  • A Commission proposal of 16 December 2025 to revise the MDR and IVDR was pending when checked and is not reflected in the dates above.

Effective from 2023-03-20

English source. The excerpt is quoted from the amending act; the inserted text uses the defined terms of Regulation (EU) 2017/745 / 93/42/EEC / 90/385/EEC and names no third-country approval.

Review clocks

What review, validation, and applicant stop-clock rules apply?

Compare countries

Agency enters IVD manufacturer, authorised-representative and distributor applications in LATMED within 10 days

clock.ivd-latmed-operator-listing-within-ten-days
Fact-level verified

The agency examines the applications of Latvian-established IVD manufacturers and authorised representatives (paragraph 27) and of IVD distributors (paragraph 28) and enters the information in LATMED within 10 days of receipt; a person that does not cover the agency's paragraph 18 expenses within the set period is removed from LATMED.

Conditions
  • Calendar days; listing is conditional on paying the annual costs under the agency fee schedule.

Effective from 2023-10-13

Latvian source. Translation: 'The agency examines the applications referred to in paragraphs 27 and 28 and, within 10 days of their receipt, enters the relevant information in LATMED. If the persons referred to in paragraphs 4, 27 and 28 do not cover the expenses referred to in paragraph 18 within the period set by the agency, the agency excludes the information on that person from LATMED.'

IVD notification procedure is completed within 10 working days by publication on the agency website

clock.ivd-notification-completed-within-ten-working-days
Fact-level verified

Within 10 working days of receiving the paragraph 8 information, the State Agency of Medicines publishes on its website at least the data received on the in vitro diagnostic device, its manufacturer, authorised representative (if applicable) or notifier and the notification number assigned by the agency; once published, the IVD notification procedure is deemed complete.

Conditions
  • The clock ends with publication, not with an approval decision; the IVD regulation mirrors paragraph 11 of the medical-device regulation No. 461.

Effective from 2023-10-13

Latvian source. Translation: 'Within 10 working days after receipt of the information specified in paragraph 8, the agency ensures public availability on its website of at least the data received within the notification procedure on the in vitro diagnostic medical device, its manufacturer, authorised representative (if applicable) or notifier and the notification number assigned by the agency. After publication of this information on the agency's website the notification procedure is considered complete.'

Agency enters manufacturer, authorised-representative and distributor applications in LATMED within 10 days

clock.latmed-operator-listing-within-ten-days
Fact-level verified

The State Agency of Medicines examines the applications of Latvian-established manufacturers and authorised representatives (paragraph 28) and of distributors supplying healthcare institutions, practitioners or other distributors (paragraph 29), and enters the information in the LATMED database within 10 days of receipt. If the person does not cover the agency's annual vigilance-system costs within the period set by the agency, the agency removes that person's information from LATMED.

Conditions
  • Calendar days ('10 dienu laikā'), unlike the 10 working days of the device notification procedure in paragraph 11.
  • Listing is conditional on paying the annual costs under paragraph 30 and the agency fee schedule.

Effective from 2023-08-23

Latvian source. Translation: 'The agency examines the applications referred to in paragraphs 28 and 29 of these Regulations and, within 10 days of their receipt, enters the relevant information in the LATMED database. If the persons referred to in paragraphs 4, 28 and 29 do not, within the period set by the agency, cover the expenses referred to in paragraph 30, the agency excludes the information on that person from the LATMED database.'

Latvian manufacturers report changes within 10 working days; the agency enters them in LATMED within 7 days

clock.manufacturer-change-entered-within-seven-days
Fact-level verified

Manufacturers with a place of business in Latvia inform the agency within 10 working days of discontinuing the placing on the market or manufacture of a device notified under paragraph 33, and of changes to the information submitted; the agency includes the submitted information in the LATMED database within seven days.

Conditions
  • Applies to manufacturers established in Latvia that have submitted device information under paragraph 33 (device and model names, MDR device type, EMDN code).

Effective from 2023-08-23

Latvian source. Translation: 'Manufacturers of medical devices whose place of business is registered in the Republic of Latvia inform of the discontinuation of placing on the market and of manufacture of the devices referred to in paragraph 33, and of changes to the information submitted under paragraph 33, within 10 working days from the occurrence of the change. The agency includes the submitted information in the LATMED database within seven days.'

Notification procedure is completed within 10 working days

clocks.notification-completed-within-ten-working-days
Fact-level verified
Statement

Within 10 working days of receiving the paragraph 9 information, the State Agency of Medicines publishes at least the data received on the medical device, its manufacturer, authorised representative or notifier and the notification number assigned by the agency. Once that information is published on the agency's website, the notification procedure is deemed complete.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

No

Target Decision Retained

No

Conditions
  • The 10 working days run from receipt of the information, and the clock stops at publication rather than at an approval decision.

Effective from 2023-08-23

Latvian source; translation: '11. Within 10 working days after receipt of the information referred to in paragraph 9 of these Regulations, the agency shall make publicly available on its website at least the data received within the notification procedure about the medical device, its manufacturer, the authorised representative (if applicable) or the notifier and the notification number assigned by the agency. After this information is published on the agency's website, the notification procedure shall be considered complete.'

Special access & derogation

Is an emergency, compassionate, custom, humanitarian, or other exceptional path available?

Compare countries

Exceptional national authorisation for devices without conformity assessment

special-access.national-authorisation-without-conformity-assessment
Fact-level verified
Statement

The State Agency of Medicines may authorise the placing on the market or putting into service of individual medical devices that have not undergone the conformity assessment procedures referred to in Article 52 of Regulation (EU) 2017/745, where the use of those devices is of essential importance for public health or for patient safety or health interests. The authorisation is granted for the time needed to carry out the necessary conformity assessment procedures, or until an alternative device becomes available, or until the use is no longer of essential importance.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Premarket Review

Local Application Required

Yes

Target Decision Retained

Yes

Conditions
  • The application must include an attestation that no alternative device with completed conformity assessment is available for treating patients, and information and test results on conformity with harmonised standards, common specifications or other technical solutions (paragraph 37.7-37.9).
  • The agency must refuse the authorisation where the device is not of essential importance, where a conforming alternative is available on the market, or where the conformity information or test results are missing (paragraph 38).
  • The examination of the application and documentation is a paid service, at EUR 528.60 for devices without conformity assessment and without CE marking (source res-lv-mk895, Annex row 63).

Effective from 2023-08-23

Latvian source; translation: '35. The agency may issue an authorisation to place on the market or put into service individual medical devices which have not undergone the conformity assessment procedures referred to in Article 52 of Regulation No. 2017/745, if the use of those devices is of essential importance for ensuring public health or patient safety or health interests. The authorisation shall be issued for the time necessary to carry out the necessary conformity assessment procedures for the medical device, or until an alternative medical device becomes available, or until its use is no longer of essential importance for ensuring public health or patient safety or health interests.'

Standards, testing & ancillary approvals

Which standards, tests, and radio, electrical, metrology, or other overlays are triggered?

Compare countries

Annual electrical-safety and functional tests under Annex 2 for active devices without CE marking, manufacturer test instructions or local support

standards.annual-electrical-safety-and-functional-tests-annex-2
Fact-level verified

A medical device in use must undergo, once a year, the electrical-safety and functional tests listed in Annex 2 of Regulation No. 461 if at least one of three conditions holds: the active class IIa, IIb or III device is not CE-marked; no manufacturer documentation is available on the electrical-safety or functional tests to be performed or their intervals; or the services of the manufacturer, its authorised representative or its representative (distributor) are not available in Latvia. Annex 2 Table 1 lists the parameters (protective conductor resistance, protective conductor leakage current, enclosure leakage current, patient leakage current for CF and BF types) and the measurement conditions; Part II adds functional tests for devices generating electrical energy for nerve, muscle or cardiac stimulation.

Conditions
  • A national in-use testing duty on the user or operator of installed devices, not a pre-market testing or certification requirement.
  • Exempted from the electrical tests: devices powered only from an autonomous source and protection class 2 devices with an electrically insulating enclosure (Annex 2, Part I, point 1).

Effective from 2023-08-23

Latvian source. Translation: '57. A medical device undergoes once a year the relevant electrical-safety and functional tests referred to in Annex 2 of these Regulations if at least one of the following circumstances exists: 57.1. the active class IIa, active class IIb or active class III device is not marked with the CE marking; 57.2. the documentation of the medical device on the electrical-safety or functional tests to be performed as determined by the manufacturer, or their intervals, is not available; 57.3. the services of the manufacturer, authorised representative or manufacturer's representative (distributor) of the medical device are not available in Latvia.' Annex 2 title: 'Elektrodrošības un funkcionālās pārbaudes aktīvām IIa, aktīvām IIb un aktīvām III klases medicīniskajām ierīcēm, kuras nav CE marķētas vai par kurām ārstniecības iestādes rīcībā nav informācijas par to ražotāja noteiktām veicamajām pārbaudēm vai to intervāliem'.

Conformity with harmonised standards gives a presumption of conformity

standards.harmonised-standards-presumption-of-conformity
Fact-level verified
Statement

Devices that conform to the relevant harmonised standards, or parts of them, whose references have been published in the Official Journal of the European Union, are presumed to conform to the requirements of Regulation (EU) 2017/745 covered by those standards. The same presumption applies to system or process requirements, including those relating to quality management systems, risk management, post-market surveillance, clinical investigations and clinical evaluation.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Local Application Required

No

Target Decision Retained

No

Conditions
  • Where no harmonised standards exist, where the relevant harmonised standards are not sufficient, or where there is a need to address public health concerns, the Commission may adopt common specifications (Article 9(1)).

Effective from 2021-05-26

English source. The parallel Latvian reference is MK noteikumi Nr. 461 paragraph 37.8 and 37.9, which require information and test results on conformity with harmonised standards or common specifications for the exceptional national authorisation.

Submission communications & appeal

How are deficiencies answered, clocks handled, and decisions escalated or appealed?

Compare countries

Appeal route: review by the Ministry of Health, then the administrative court

appeal.agency-decisions-appealable-to-ministry-and-court
Fact-level verified
Statement

Administrative acts issued by the director of the State Agency of Medicines (other than the decision referred to in paragraph 8 about officials' decisions) and actual action may be contested before the Ministry of Health; the Ministry's decision may then be appealed to the administrative court. Decisions and actual action of officials of the agency's structural units may be contested by submitting an application to the director of the agency, and the director's decision may be appealed to the administrative court.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Premarket Review

Local Application Required

Yes

Target Decision Retained

Yes

Conditions
  • The procedure and time limits for the contest and appeal follow the Administrative Procedure Law; the statute sets the forum, not the clock.

Latvian source; translation: '8. Decisions and actual action of officials of the structural units of the agency may be contested by submitting a relevant application to the director of the agency. The decision of the director of the agency may be appealed to the administrative court. 9. Administrative acts issued by the director of the agency (except the decision referred to in paragraph 8 of these Regulations) and actual action may be contested in the Ministry of Health. The decision of the Ministry of Health may be appealed to the administrative court.'

UDI, listing & traceability

Which UDI, device listing, database, and traceability duties apply?

Compare countries

Healthcare institutions must store supplied UDIs electronically for at least two years

udi.healthcare-institutions-store-udi-two-years
Fact-level verified
Statement

Healthcare institutions must store electronically, for at least two years, the unique identifiers of the active class IIa, active class IIb and active class III medical devices supplied to them.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Postmarket Surveillance

Local Application Required

No

Target Decision Retained

No

Conditions
  • The paragraph sits in the section on distribution, use and operation of devices and was given its current wording by Cabinet Regulation No. 824 of 22 December 2025.
  • Traceability duties for the persons in paragraph 9 - transaction records for every transaction other than with natural-person consumers, and immediate notification to the agency and the Inspectorate of suspension or recall actions - are in paragraphs 17.1-17.3.

Effective from 2025-12-24

Latvian source; translation: '47.5. for at least two years, store electronically the unique identifiers of the active class IIa, active class IIb and active class III medical devices supplied to them.' The Union-level UDI system and the manufacturer's UDI assignment and EUDAMED registration duties are in Articles 27 and 29 of Regulation (EU) 2017/745 (source res-lv-mdr).

Vigilance & incident reporting

What is reportable, by whom, where, in what format, and by what deadline?

Compare countries

Latvian healthcare institutions report incidents to the agency within three days

vigilance.latvian-healthcare-institution-signal-report-three-days
Fact-level verified
Statement

The representative of a healthcare institution must send the State Agency of Medicines a medical device user incident report (signal report) within three days of a serious incident or a potential serious incident with a medical device, using the form in Annex 3 to the regulation or the electronic reporting form on the agency's website, and must inform the manufacturer, authorised representative or distributor of any deterioration of device parameters or malfunction and of any inaccuracies on labels or in instructions for use that could cause or have caused death or serious harm to a patient, user or third person.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Postmarket Surveillance

Local Application Required

Yes

Target Decision Retained

No

Conditions
  • A user or patient (or their representative) must likewise inform the agency within three days of a serious or potentially serious incident, using the Annex 4 form (paragraph 74).
  • On receiving a manufacturer's initial report of a serious incident occurring in Latvia the agency registers the report, opens a vigilance case, may request further information, supervises the investigation, may initiate an independent investigation, and assesses the adequacy of the manufacturer's proposed field safety corrective action (paragraph 76).

Effective from 2023-08-23

Latvian source; translation: '70. The representative of a healthcare institution shall, within three days after a serious incident or a potential serious incident with a medical device, send to the agency a medical device user incident report (hereinafter - the signal report), using the template given in Annex 3 to these Regulations or the electronic reporting form available on the agency's website, and shall inform the manufacturer or authorised representative, or distributor, of any deterioration of the parameters of the medical device or malfunction, as well as of all inaccuracies on labels or in instructions for use which may cause or have caused the death or serious health harm of a patient, user or third person.'

Manufacturer serious-incident reporting: 15 days, 10 days, 2 days

vigilance.manufacturer-serious-incident-reporting-deadlines
Fact-level verified
Statement

Manufacturers of devices made available on the Union market must report any serious incident to the relevant competent authorities not later than 15 days after becoming aware of the incident. For a serious public health threat the report must be provided immediately and not later than 2 days after the manufacturer becomes aware of the threat. In the event of death or an unanticipated serious deterioration in a person's state of health, the report must be provided immediately after the manufacturer establishes or suspects a causal relationship, and not later than 10 days after becoming aware of the incident. Field safety corrective actions must be reported in advance of being undertaken, except in urgent cases.

Source Approval

Target Jurisdiction Id

Edge Type

Market Access Strength

Regulatory Layer

Postmarket Surveillance

Local Application Required

No

Target Decision Retained

No

Conditions
  • Reports are submitted through the electronic system referred to in Article 92, which is EUDAMED.
  • Field safety corrective actions undertaken in a third country must also be reported where the device is legally made available on the Union market and the reason is not limited to the third-country device (Article 87(1)(b)).
  • In Latvia, healthcare institutions and users report to the State Agency of Medicines within three days (see vigilance.latvian-healthcare-institution-signal-report-three-days).

Effective from 2021-05-26

English source.

Related structured datasets

Classification systems · 1 record
Open EU MDR classes I, Is, Im, Ir, IIa, IIb and III →
Id

latvia:medical-device

Jurisdiction Id

latvia

Domains
  • medical-device
Name

EU MDR classes I, Is, Im, Ir, IIa, IIb and III

Description

National projection of the directly applicable EU MDR classification. The canonical class axis and rules are maintained in eu:medical-device; the Latvian regulation adds no national class rule of its own.

Classes
  • Id

    i

    Label

    Class I

    Normalized Risk Level

    low

  • Id

    is

    Label

    Class Is

    Normalized Risk Level

    low

  • Id

    im

    Label

    Class Im

    Normalized Risk Level

    low

  • Id

    ir

    Label

    Class Ir

    Normalized Risk Level

    low

  • Id

    iia

    Label

    Class IIa

    Normalized Risk Level

    medium

  • Id

    iib

    Label

    Class IIb

    Normalized Risk Level

    high

  • Id

    iii

    Label

    Class III

    Normalized Risk Level

    highest

Regulator

ZVA

Official Domains
  • likumi.lv
  • zva.gov.lv
  • eur-lex.europa.eu
Source Status

official-source-verified

Reference Sources
  • Title

    Medicīnisko ierīču noteikumi (Cabinet Regulation No. 461 of 15.08.2023, in force 23.08.2023), § 1 and § 9 — scope and the IIa/IIb/III notification

    Url

    https://likumi.lv/ta/id/344674-medicinisko-iericu-noteikumi

    Reviewed On

    2026-09-16

    Supports

    § 1 makes the regulation applicable to medical devices within the meaning of Art. 2(1) of Regulation (EU) 2017/745 and to the accessories and products in Art. 1(4) of that regulation, so the class is the Union class; § 9 then imposes a national notification on persons who begin to place IIa, IIb and III class devices on the Latvian market, which presupposes the Union class rather than creating a Latvian one. No article of the regulation defines its own class axis.

  • Title

    Zāļu valsts aģentūra — Pirms laišanas apgrozībā (medical device manufacturers and authorised representatives)

    Url

    https://www.zva.gov.lv/lv/industrijai/medicinisko-iericu-razotaji-pilnvarotie-parstavji/pirms-laisanas-apgroziba

    Reviewed On

    2026-09-16

    Supports

    The agency's own page groups devices by the Union classes when it explains the market: zema riska (I, Is, Im, Ir klase), vidēja riska (IIa, IIb) and augsta riska (III klase), with examples of each. It is a regulator topic page rather than the instrument, so it is cited only for the allocation of the class axis to the Union scheme.

Inherited From Scheme Id

eu:medical-device

Source Title

Regulation (EU) 2017/745, Art. 51 and Annex VIII

Source Url

https://eur-lex.europa.eu/eli/reg/2017/745/oj

Verified On

2026-09-16

Source Supports
  • class-axis
  • classification-rules
Registration pathways, prior approvals and planning · 1 record
Open Latvia registration →
Country

Latvia

Jurisdiction Id

latvia

Country Code

LV

Flag

🇱🇻

Regulator

Zāļu valsts aģentūra (State Agency of Medicines)

Regulator Abbrev

ZVA

Region

europe

Tier

3

Risk Classification

4-class (I, IIa, IIb, III) — EU MDR

Classes
  • Id

    class-i

    Class Name

    Class I

    Risk Level

    low

    Pathway

    Self-declaration (no notified body)

    Official Timeline
    Min

    0

    Max

    0

    Unit

    days

    Verification Status

    official-verified

    Official Source
    Title

    EUR-Lex Regulation (EU) 2017/745 (MDR)

    Url

    https://eur-lex.europa.eu/eli/reg/2017/745/oj

    Accessed Date

    2026-09-16

    Realistic Timeline
    Min

    6

    Max

    9

    Notes
    • MDR Art. 52(7): non-sterile, non-measuring, non-reusable-surgical Class I devices are self-declared, so no authority or notified body reviews the file and there is no review clock
    • Elapsed time is EUDAMED actor and device registration plus the Latvian duties: a class I manufacturer whose place of business is registered in Latvia applies to the agency under § 28 of Cabinet Regulation No. 461 and the agency enters the information in the LATMED database within ten days under § 31
    Clinical Trial Required

    No

    Local Testing Required

    No

    Gmp Required

    Yes

  • Id

    latvia-notification-publication

    Class Name

    ZVA publication of a IIa, IIb or III class device notification, which completes the notification procedure

    Risk Level

    high

    Pathway

    National notification under § 9 of Cabinet Regulation No. 461

    Official Timeline
    Min

    10

    Max

    10

    Unit

    working-days

    Verification Status

    official-verified

    Official Source
    Title

    Medicīnisko ierīču noteikumi (Cabinet Regulation No. 461 of 15.08.2023, in force 23.08.2023; current redaction in force from 01.01.2026) — § 9 the IIa/IIb/III notification, § 11 the ten-working-day publication, §§ 28, 29 and 41.1 the LATMED registration, § 31 the ten-day LATMED entry and §§ 70 and 74.1 the three-day signal reports

    Url

    https://likumi.lv/ta/id/344674-medicinisko-iericu-noteikumi

    Effective Date

    2026-01-01

    Accessed Date

    2026-09-16

    Realistic Timeline
    Min

    10

    Max

    25

    Unit

    working-days

    Notes
    • Verbatim § 11: '10 darbdienu laikā pēc šo noteikumu 9. punktā minētās informācijas saņemšanas aģentūra savā tīmekļvietnē nodrošina publisku pieejamību vismaz paziņošanas procedūras ietvaros saņemtajiem datiem par medicīnisko ierīci, tās ražotāju, pilnvaroto pārstāvi (ja attiecināms) vai paziņotāju un aģentūras piešķirto paziņojuma numuru. Pēc šīs informācijas publiskošanas aģentūras tīmekļvietnē paziņošanas procedūra uzskatāma par pabeigtu.'
    • The duty in § 9 falls on persons who begin to place IIa, IIb and III class devices on the Latvian market and requires the completed notification form (Annex 1) together with a copy of the EU declaration of conformity and copies of the valid notified-body certificates, so one clock spans three classes rather than belonging to any single one
    • The clock stops at publication, not at an approval decision, and the notification does not gate the placing of the device on the market
    Clinical Trial Required

    No

    Local Testing Required

    No

    Gmp Required

    No

  • Id

    latvia-latmed-registration-entry

    Class Name

    ZVA entry of a manufacturer's or distributor's application into the LATMED database

    Risk Level

    low

    Pathway

    National registration under §§ 28, 29 and 41.1 of Cabinet Regulation No. 461

    Official Timeline
    Min

    10

    Max

    10

    Unit

    days

    Verification Status

    official-verified

    Official Source
    Title

    Medicīnisko ierīču noteikumi (Cabinet Regulation No. 461 of 15.08.2023, in force 23.08.2023; current redaction in force from 01.01.2026) — § 9 the IIa/IIb/III notification, § 11 the ten-working-day publication, §§ 28, 29 and 41.1 the LATMED registration, § 31 the ten-day LATMED entry and §§ 70 and 74.1 the three-day signal reports

    Url

    https://likumi.lv/ta/id/344674-medicinisko-iericu-noteikumi

    Effective Date

    2026-01-01

    Accessed Date

    2026-09-16

    Realistic Timeline
    Min

    10

    Max

    20

    Unit

    days

    Notes
    • Verbatim § 31: 'Aģentūra izskata šo noteikumu 28. un 29. punktā minētos iesniegumus un 10 dienu laikā pēc to saņemšanas ievada attiecīgo informāciju LATMED datubāzē.'
    • The clock is route-wide and not class-specific: § 28 covers the manufacturers of class I devices and the assemblers of systems and procedure packs, and § 29 covers distributors, whichever class they handle
    • The registration is a precondition of distribution rather than of the CE route: § 41.1 provides that distributors may make devices available on the Latvian market only if the information about them as a distributor has been entered in the LATMED database, and § 41.2 extends that to manufacturers, importers and authorised representatives from 1 January 2026
    • The same section fixes a ten-working-day change-report clock (§ 32) and a ten-working-day discontinuation report with a seven-day agency entry (§ 34), which are not separately published here
    Clinical Trial Required

    No

    Local Testing Required

    No

    Gmp Required

    No

  • Id

    latvia-free-sale-certificate

    Class Name

    ZVA free-sale certificate for a device manufactured in Latvia

    Risk Level

    low

    Pathway

    Paid service of the State Agency of Medicines under its published fee schedule

    Official Timeline
    Min

    30

    Max

    30

    Unit

    days

    Verification Status

    official-verified

    Official Source
    Title

    Zāļu valsts aģentūra — Pirms laišanas apgrozībā: Brīvās tirdzniecības sertifikāta saņemšana — 'Brīvās tirdzniecības sertifikātu ZVA izsniedz 30 dienu laikā pēc iesnieguma un tam pievienoto dokumentu saņemšanas.'

    Url

    https://www.zva.gov.lv/lv/industrijai/medicinisko-iericu-razotaji-pilnvarotie-parstavji/pirms-laisanas-apgroziba

    Accessed Date

    2026-09-16

    Realistic Timeline
    Min

    30

    Max

    45

    Unit

    days

    Notes
    • Verbatim from ZVA's page: 'Brīvās tirdzniecības sertifikātu ZVA izsniedz 30 dienu laikā pēc iesnieguma un tam pievienoto dokumentu saņemšanas.' The agency issues the certificate in Latvian and English on the application of a manufacturer of a medical device or an in vitro diagnostic medical device, for devices manufactured in Latvia that are marked with the CE marking
    • The period is route-wide and class-independent, and it is published by the agency rather than in the regulation: § 23 of Cabinet Regulation No. 461 provides for the certificate and the costs but fixes no period
    • This is an export and free-sale certificate, not a route onto the Latvian market; the service is chargeable at EUR 185.41 under item 54 of the agency fee schedule
    Clinical Trial Required

    No

    Local Testing Required

    No

    Gmp Required

    No

  • Id

    latvia-incident-signal-report

    Class Name

    Three-day signal report to ZVA after a serious incident or a potentially serious incident with a device

    Risk Level

    medium

    Pathway

    National vigilance clock under §§ 70 and 74.1 of Cabinet Regulation No. 461

    Official Timeline
    Min

    3

    Max

    3

    Unit

    days

    Verification Status

    official-verified

    Official Source
    Title

    Medicīnisko ierīču noteikumi (Cabinet Regulation No. 461 of 15.08.2023, in force 23.08.2023; current redaction in force from 01.01.2026) — § 9 the IIa/IIb/III notification, § 11 the ten-working-day publication, §§ 28, 29 and 41.1 the LATMED registration, § 31 the ten-day LATMED entry and §§ 70 and 74.1 the three-day signal reports

    Url

    https://likumi.lv/ta/id/344674-medicinisko-iericu-noteikumi

    Effective Date

    2026-01-01

    Accessed Date

    2026-09-16

    Realistic Timeline
    Min

    3

    Max

    10

    Unit

    days

    Notes
    • Verbatim § 70: 'Ārstniecības iestādes pārstāvis triju dienu laikā pēc nopietna negadījuma vai varbūtēja nopietna negadījuma ar medicīnisko ierīci nosūta aģentūrai medicīniskās ierīces lietotāja negadījuma ziņojumu (turpmāk – signālziņojums) ... un informē ražotāju vai pilnvaroto pārstāvi, vai izplatītāju'
    • Verbatim § 74.1: the person who uses the device, or their representative, 'triju dienu laikā informē par to aģentūru, iesniedzot signālziņojumu'
    • This is a national reporting clock, not a market-entry clock, and it applies to every device class alike
    Clinical Trial Required

    No

    Local Testing Required

    No

    Gmp Required

    No

Prior Approvals
  • Authority

    FDA 510(k)/PMA

    Accepted

    No

    Benefit

    No substitute for EU MDR conformity assessment; useful as predicate documentation in the technical file

Key Requirements
  • EU Authorized Representative for non-EU manufacturers (MDR Article 11), whose place of business must be registered in Latvia and who must be entered in the LATMED database
  • Notification to ZVA before beginning to place a IIa, IIb or III class device on the Latvian market, on the notification form with the EU declaration of conformity and the valid notified-body certificates; the procedure is complete once ZVA publishes the data, within ten working days (§§ 9 and 11 of Cabinet Regulation No. 461)
  • Registration in the LATMED database — required of distributors before they make devices available (§ 41.1) and of manufacturers, importers and authorised representatives from 1 January 2026 (§ 41.2); ZVA enters the information within ten days of the application (§ 31)
  • Information for users and patients under Annex I section 23 of Regulation (EU) 2017/745 must be provided in the Latvian state language, with a narrow healthcare-institution exception subject to that institution's consent (§ 6)
  • Annual vigilance-system fee: EUR 105.20 for class I and other (remaining) devices and class A IVDs, EUR 201.90 for IIa, IIb and III devices and the listed, self-test and B, C and D IVDs, payable per manufacturer, authorised representative or distributor (Cabinet Regulation No. 895, annex items 62.1 and 62.2, funding the duty in § 30)
  • EUDAMED actor and device registration, with the first four EUDAMED modules mandatory since 28 May 2026
  • The operator of a site where a device producing ionizing radiation is used needs the notification, registration certificate or licence of the State Environmental Service Radiation Safety Centre, with state fees of EUR 97 (registration certificate) or EUR 170 (licence) under Cabinet Regulation No. 65 § 63
  • A device that is a legal measuring instrument must satisfy PTAC's state metrological supervision, including type approval or conformity assessment with initial verification and repeated verification, against the list in Cabinet Regulation No. 289
  • Electrical and electronic equipment and batteries placed on the Latvian market carry the producer registration and data-maintenance payment of Cabinet Regulation No. 331, including for the authorised representative of a foreign producer
  • Device features that are radio equipment fall under Cabinet Regulation No. 215, whose market-surveillance authority is PTAC and whose use-surveillance body is SIA 'Elektroniskie sakari'
  • Clinical investigations of medical devices and performance studies of IVDs are examined by ZVA, with documentation charges of EUR 1,500, EUR 900 for substantial modifications and EUR 900 for resumption after suspension
Local Rep Required

Yes

Local Rep Name

EU Authorized Representative

Mdsap Accepted

No

Mdsap Benefit

ISO 13485 accepted as QMS evidence

Registration Validity

5 years (CE certificate)

Last Updated

2026-09-16

Verification Status

partially-verified

Official Sources
  • Title

    EUR-Lex Regulation (EU) 2017/745 (MDR)

    Url

    https://eur-lex.europa.eu/eli/reg/2017/745/oj

    Accessed Date

    2026-09-16

  • Title

    Commission Implementing Regulation (EU) 2026/977, Art. 2 — maximum notified-body conformity assessment timelines (30 + 120/90 parallel + 20 days)

    Url

    https://eur-lex.europa.eu/eli/reg_impl/2026/977/oj

    Effective Date

    2027-02-25

    Accessed Date

    2026-09-16

  • Title

    Medicīnisko ierīču noteikumi (Cabinet Regulation No. 461 of 15.08.2023, in force 23.08.2023; current redaction in force from 01.01.2026) — § 9 the IIa/IIb/III notification, § 11 the ten-working-day publication, §§ 28, 29 and 41.1 the LATMED registration, § 31 the ten-day LATMED entry and §§ 70 and 74.1 the three-day signal reports

    Url

    https://likumi.lv/ta/id/344674-medicinisko-iericu-noteikumi

    Effective Date

    2026-01-01

    Accessed Date

    2026-09-16

  • Title

    Zāļu valsts aģentūra — Pirms laišanas apgrozībā: Brīvās tirdzniecības sertifikāta saņemšana — 'Brīvās tirdzniecības sertifikātu ZVA izsniedz 30 dienu laikā pēc iesnieguma un tam pievienoto dokumentu saņemšanas.'

    Url

    https://www.zva.gov.lv/lv/industrijai/medicinisko-iericu-razotaji-pilnvarotie-parstavji/pirms-laisanas-apgroziba

    Accessed Date

    2026-09-16

Reviewed On

2026-09-16

Process
Template Id

default

Status

planning-template

Usage Rule

Maintained planning steps and estimates, not verified regulator deadlines.

Steps
  • Step

    1

    Title

    Pre-Submission Preparation

    Description

    Gather technical documentation, quality management system (QMS) records, and clinical data required by ZVA. Appoint a EU Authorized Representative.

    Duration

    1-3 months

    Icon

    📋

  • Step

    2

    Title

    Application Submission

    Description

    Submit complete registration dossier to ZVA including device description, risk analysis, and testing reports.

    Duration

    1-2 weeks

    Icon

    📤

  • Step

    3

    Title

    Administrative Review

    Description

    ZVA reviews application for completeness. May request additional documents or clarifications.

    Duration

    2-4 weeks

    Icon

    🔍

  • Step

    4

    Title

    Technical Evaluation

    Description

    In-depth technical assessment of device safety and performance. ZVA may issue questions.

    Duration

    0 days

    Icon

    ⚙️

  • Step

    5

    Title

    Registration Approval

    Description

    Upon successful review, ZVA issues Latvia market authorization certificate.

    Duration

    1-2 weeks

    Icon

    ✅

Government fee schedules · 1 record
Open Latvia fees →
Jurisdiction Id

latvia

Country

Latvia

Country Code

LV

Authority

ZVA

Low Risk Local
Min

105.2

Max

185.41

Currency

EUR

Per Product

No

High Risk Local
Min

201.9

Max

2000

Currency

EUR

Per Product

No

Details
  • Id

    class-i-and-a-class-ivd-annual-vigilance-fee

    Item

    Annual fee for maintaining the medical device vigilance system for class I and other (remaining) medical devices and class A in vitro diagnostic medical devices (Cabinet Regulation No. 895, annex item 62.1)

    Currency

    EUR

    Amount Local

    105.2

    Amount Local Formatted

    EUR 105.20

    Frequency

    Per manufacturer, authorised representative or distributor, per year

    Notes

    Verbatim: 'par I klases medicīnisko ierīču un citu (pārējo) un A klases in vitro diagnostikas medicīnisko ierīču vigilances sistēmas darbības nodrošināšanu | 1 ražotājs vai 1 pilnvarotais pārstāvis, vai 1 izplatītājs | 105,20'. The charge is the statutory funding of the duty in § 30 of Cabinet Regulation No. 461, under which the persons registered under §§ 4, 28 and 29 cover the agency's vigilance-system costs each calendar year in the manner and amount set by the agency fee schedule.

    Amount Status

    exact-current

    Verification Status

    official-verified

    Source Url

    https://likumi.lv/ta/id/357532-zalu-valsts-agenturas-maksas-pakalpojumu-cenradis

    Source Title

    Zāļu valsts aģentūras maksas pakalpojumu cenrādis (Cabinet Regulation No. 895 of 18.12.2024, in force 01.01.2025; Latvijas Vēstnesis 249, 20.12.2024) — the medical-device items 8.1, 54, 55, 56, 57, 61, 62.1, 62.2 and 63 of the annex

    Source Effective Date

    2025-01-01

    Verified On

    2026-09-16

  • Id

    higher-class-annual-vigilance-fee

    Item

    Annual fee for maintaining the medical device vigilance system for class IIa, IIb and III (including class I) medical devices and A-list, B-list and self-test, class B, class C and class D (including class A) in vitro diagnostic medical devices (Cabinet Regulation No. 895, annex item 62.2)

    Currency

    EUR

    Amount Local

    201.9

    Amount Local Formatted

    EUR 201.90

    Frequency

    Per manufacturer, authorised representative or distributor, per year

    Notes

    Verbatim: 'par IIa, IIb un III klases (ietverot arī I klases) medicīnisko ierīču, A saraksta, B saraksta un pašpārbaudes (ietverot arī citas (pārējās)), B klases, C klases un D klases (ietverot arī A klases) in vitro diagnostikas medicīnisko ierīču vigilances sistēmas darbības nodrošināšanu | 1 ražotājs vai 1 pilnvarotais pārstāvis, vai 1 izplatītājs | 201,90'. This is the line that makes the Latvian tariff genuinely risk-class-differentiated.

    Amount Status

    exact-current

    Verification Status

    official-verified

    Source Url

    https://likumi.lv/ta/id/357532-zalu-valsts-agenturas-maksas-pakalpojumu-cenradis

    Source Title

    Zāļu valsts aģentūras maksas pakalpojumu cenrādis (Cabinet Regulation No. 895 of 18.12.2024, in force 01.01.2025; Latvijas Vēstnesis 249, 20.12.2024) — the medical-device items 8.1, 54, 55, 56, 57, 61, 62.1, 62.2 and 63 of the annex

    Source Effective Date

    2025-01-01

    Verified On

    2026-09-16

  • Id

    free-sale-certificate

    Item

    Issue of a medical device free-sale certificate (Cabinet Regulation No. 895, annex item 54)

    Currency

    EUR

    Amount Local

    185.41

    Amount Local Formatted

    EUR 185.41

    Frequency

    Per certificate

    Notes

    Verbatim: 'Medicīniskās ierīces brīvās tirdzniecības sertifikāta izsniegšana | 1 sertifikāts | 185,41'. ZVA publishes the service period for this certificate on its own site: 'Brīvās tirdzniecības sertifikātu ZVA izsniedz 30 dienu laikā pēc iesnieguma un tam pievienoto dokumentu saņemšanas.'

    Amount Status

    exact-current

    Verification Status

    official-verified

    Source Url

    https://likumi.lv/ta/id/357532-zalu-valsts-agenturas-maksas-pakalpojumu-cenradis

    Source Title

    Zāļu valsts aģentūras maksas pakalpojumu cenrādis (Cabinet Regulation No. 895 of 18.12.2024, in force 01.01.2025; Latvijas Vēstnesis 249, 20.12.2024) — the medical-device items 8.1, 54, 55, 56, 57, 61, 62.1, 62.2 and 63 of the annex

    Source Effective Date

    2025-01-01

    Verified On

    2026-09-16

  • Id

    clinical-investigation-documentation-review

    Item

    Examination of the documentation of a clinical investigation of a medical device or of a performance study of an in vitro diagnostic medical device (Cabinet Regulation No. 895, annex item 55)

    Currency

    EUR

    Amount Local

    1500

    Amount Local Formatted

    EUR 1,500.00

    Frequency

    Per documentation examination

    Notes

    Verbatim: 'Medicīnisko ierīču klīniskā pētījuma un in vitro diagnostikas medicīnisko ierīču veiktspējas pētījuma dokumentācijas ekspertīze | 1 dokumentācijas ekspertīze | 1500,00'.

    Amount Status

    exact-current

    Verification Status

    official-verified

    Source Url

    https://likumi.lv/ta/id/357532-zalu-valsts-agenturas-maksas-pakalpojumu-cenradis

    Source Title

    Zāļu valsts aģentūras maksas pakalpojumu cenrādis (Cabinet Regulation No. 895 of 18.12.2024, in force 01.01.2025; Latvijas Vēstnesis 249, 20.12.2024) — the medical-device items 8.1, 54, 55, 56, 57, 61, 62.1, 62.2 and 63 of the annex

    Source Effective Date

    2025-01-01

    Verified On

    2026-09-16

  • Id

    clinical-investigation-substantial-modification-review

    Item

    Examination of the documentation of a substantial modification of a clinical investigation of a medical device or of a performance study of an in vitro diagnostic medical device (Cabinet Regulation No. 895, annex item 56)

    Currency

    EUR

    Amount Local

    900

    Amount Local Formatted

    EUR 900.00

    Frequency

    Per documentation examination

    Notes

    Verbatim: 'Medicīnisko ierīču klīniskā pētījuma un in vitro diagnostikas medicīnisko ierīču veiktspējas pētījuma būtisku izmaiņu dokumentācijas ekspertīze | 1 dokumentācijas ekspertīze | 900,00'.

    Amount Status

    exact-current

    Verification Status

    official-verified

    Source Url

    https://likumi.lv/ta/id/357532-zalu-valsts-agenturas-maksas-pakalpojumu-cenradis

    Source Title

    Zāļu valsts aģentūras maksas pakalpojumu cenrādis (Cabinet Regulation No. 895 of 18.12.2024, in force 01.01.2025; Latvijas Vēstnesis 249, 20.12.2024) — the medical-device items 8.1, 54, 55, 56, 57, 61, 62.1, 62.2 and 63 of the annex

    Source Effective Date

    2025-01-01

    Verified On

    2026-09-16

  • Id

    clinical-investigation-resumption-review

    Item

    Examination of the documentation for resuming a clinical investigation of a medical device or a performance study of an in vitro diagnostic medical device after the investigation was suspended (Cabinet Regulation No. 895, annex item 57)

    Currency

    EUR

    Amount Local

    900

    Amount Local Formatted

    EUR 900.00

    Frequency

    Per documentation examination

    Notes

    Verbatim: 'Medicīnisko ierīču klīniskā pētījuma un in vitro diagnostikas medicīnisko ierīču veiktspējas pētījuma atjaunošana pēc klīniskā pētījuma apturēšanas | 1 dokumentācijas ekspertīze | 900,00'.

    Amount Status

    exact-current

    Verification Status

    official-verified

    Source Url

    https://likumi.lv/ta/id/357532-zalu-valsts-agenturas-maksas-pakalpojumu-cenradis

    Source Title

    Zāļu valsts aģentūras maksas pakalpojumu cenrādis (Cabinet Regulation No. 895 of 18.12.2024, in force 01.01.2025; Latvijas Vēstnesis 249, 20.12.2024) — the medical-device items 8.1, 54, 55, 56, 57, 61, 62.1, 62.2 and 63 of the annex

    Source Effective Date

    2025-01-01

    Verified On

    2026-09-16

  • Id

    medical-device-cost-effectiveness-expertise

    Item

    Expertise on the cost-effectiveness of medical devices for one diagnosis or a group of similar diagnoses, one (single) patient group and one (single) comparable therapy (Cabinet Regulation No. 895, annex item 61)

    Currency

    EUR

    Amount Local

    1200

    Amount Local Formatted

    EUR 1,200.00

    Frequency

    Per documentation examination

    Notes

    Verbatim: 'Ekspertīze par zāļu ārstniecisko un izmaksu efektivitāti vai par medicīnisko ierīču izmaksu efektivitāti vienai diagnozei vai līdzīgu diagnožu grupai, vienai (vienotai) pacientu grupai un vienai (vienotai) salīdzināmai terapijai | 1 dokumentācijas ekspertīze | 1200,00'. The item covers both the medicines and the medical-device expertise; the device leg is what is recorded here.

    Amount Status

    exact-current

    Verification Status

    official-verified

    Source Url

    https://likumi.lv/ta/id/357532-zalu-valsts-agenturas-maksas-pakalpojumu-cenradis

    Source Title

    Zāļu valsts aģentūras maksas pakalpojumu cenrādis (Cabinet Regulation No. 895 of 18.12.2024, in force 01.01.2025; Latvijas Vēstnesis 249, 20.12.2024) — the medical-device items 8.1, 54, 55, 56, 57, 61, 62.1, 62.2 and 63 of the annex

    Source Effective Date

    2025-01-01

    Verified On

    2026-09-16

  • Id

    non-ce-marked-device-market-placement-review

    Item

    Examination of the application and documentation to place on the market or put into service individual medical devices or in vitro diagnostic medical devices that have not undergone the conformity assessment procedures laid down in the regulatory enactments and are not marked with the CE marking (Cabinet Regulation No. 895, annex item 63)

    Currency

    EUR

    Amount Local

    528.6

    Amount Local Formatted

    EUR 528.60

    Frequency

    Per documentation examination

    Notes

    Verbatim: 'Iesnieguma un dokumentācijas ekspertīze, lai laistu tirgū vai nodotu ekspluatācijā atsevišķas medicīniskās ierīces vai in vitro diagnostikas medicīniskās ierīces, kurām nav veiktas normatīvajos aktos paredzētās atbilstības novērtēšanas procedūras un kuras nav marķētas ar CE marķējumu | 1 dokumentācijas ekspertīze | 528,60'. This is the Latvian charge for the derogation route.

    Amount Status

    exact-current

    Verification Status

    official-verified

    Source Url

    https://likumi.lv/ta/id/357532-zalu-valsts-agenturas-maksas-pakalpojumu-cenradis

    Source Title

    Zāļu valsts aģentūras maksas pakalpojumu cenrādis (Cabinet Regulation No. 895 of 18.12.2024, in force 01.01.2025; Latvijas Vēstnesis 249, 20.12.2024) — the medical-device items 8.1, 54, 55, 56, 57, 61, 62.1, 62.2 and 63 of the annex

    Source Effective Date

    2025-01-01

    Verified On

    2026-09-16

  • Id

    classification-and-clinical-evaluation-consultation

    Item

    Consultation on questions concerning the classification, clinical evaluation and performance evaluation of medical devices and in vitro diagnostic medical devices (Cabinet Regulation No. 895, annex item 8.1)

    Currency

    EUR

    Amount Local

    2000

    Amount Local Formatted

    EUR 2,000.00

    Frequency

    Per consultation

    Notes

    Verbatim: 'par jautājumiem, kas skar zāļu reģistrācijas procedūras, tai skaitā par izmaiņām zāļu reģistrāciju procedūrās; par jautājumiem, kas skar medicīnisko ierīču un in vitro diagnostikas medicīnisko ierīču klasificēšanu, klīnisko izvērtēšanu un veiktspējas izvērtēšanu; par klīnisko pārbaužu preklīniskajiem, klīniskajiem un pētāmo zāļu kvalitātes jautājumiem | 1 konsultācija | 2000,00'. The item is shared with the medicines registration questions; only the device leg is recorded here. The service is optional and confirms the Union class rather than replacing the manufacturer's own Annex VIII classification.

    Amount Status

    exact-current

    Verification Status

    official-verified

    Source Url

    https://likumi.lv/ta/id/357532-zalu-valsts-agenturas-maksas-pakalpojumu-cenradis

    Source Title

    Zāļu valsts aģentūras maksas pakalpojumu cenrādis (Cabinet Regulation No. 895 of 18.12.2024, in force 01.01.2025; Latvijas Vēstnesis 249, 20.12.2024) — the medical-device items 8.1, 54, 55, 56, 57, 61, 62.1, 62.2 and 63 of the annex

    Source Effective Date

    2025-01-01

    Verified On

    2026-09-16

  • Id

    radiation-registration-certificate-state-fee

    Item

    State fee for the issue of a registration certificate for activities with ionizing radiation sources (Cabinet Regulation No. 65, § 63.1)

    Currency

    EUR

    Amount Local

    97

    Amount Local Formatted

    EUR 97.00

    Frequency

    Per registration certificate

    Notes

    Verbatim: 'par reģistrācijas apliecības izsniegšanu darbībām ar jonizējošā starojuma avotiem – 97 euro'. § 62 requires the fee to be paid before the application is submitted, by bank transfer or through the payment module in the State Environmental Service information system. This is a use-site charge on the operator, not a device charge.

    Amount Status

    exact-current

    Verification Status

    official-verified

    Source Url

    https://likumi.lv/ta/id/320612-darbibu-ar-jonizejosa-starojuma-avotiem-pazinosanas-registresanas-un-licencesanas-noteikumi

    Source Title

    Darbību ar jonizējošā starojuma avotiem paziņošanas, reģistrēšanas un licencēšanas noteikumi (Cabinet Regulation No. 65 of 28.01.2021, in force 01.02.2021) — § 63 state fees for the radiation registration certificate and licence

    Source Effective Date

    2021-02-01

    Verified On

    2026-09-16

  • Id

    radiation-licence-state-fee

    Item

    State fee for the issue of a licence for activities with ionizing radiation sources (Cabinet Regulation No. 65, § 63.2)

    Currency

    EUR

    Amount Local

    170

    Amount Local Formatted

    EUR 170.00

    Frequency

    Per licence

    Notes

    Verbatim: 'par licences izsniegšanu darbībām ar jonizējošā starojuma avotiem – 170 euro'. Amendment charges sit alongside it: EUR 54 for changes to a registration certificate (§ 63.3), EUR 84 for amendments to a licence (§ 63.4) and EUR 10 for the changes listed in § 64 (§ 63.5).

    Amount Status

    exact-current

    Verification Status

    official-verified

    Source Url

    https://likumi.lv/ta/id/320612-darbibu-ar-jonizejosa-starojuma-avotiem-pazinosanas-registresanas-un-licencesanas-noteikumi

    Source Title

    Darbību ar jonizējošā starojuma avotiem paziņošanas, reģistrēšanas un licencēšanas noteikumi (Cabinet Regulation No. 65 of 28.01.2021, in force 01.02.2021) — § 63 state fees for the radiation registration certificate and licence

    Source Effective Date

    2021-02-01

    Verified On

    2026-09-16

Notes
  • Latvia operates no national device authorisation, so there is no authorisation fee: the fee record consists of the State Agency of Medicines charges for the acts it performs under Cabinet Regulation No. 461, plus the State Environmental Service radiation registration and licence state fees.
  • The device schedule is only partly differentiated by device risk class. The recurring annual vigilance-system fee is the one line that tracks the class axis exactly: EUR 105.20 for class I and other (remaining) medical devices and class A IVDs (item 62.1) against EUR 201.90 for class IIa, IIb and III devices and A-list, B-list and self-test, class B, C and D IVDs (item 62.2), payable per manufacturer, authorised representative or distributor. Every other line is a class-independent charge for a certificate, an expert examination or a consultation.
  • The two bands are the reporter's grouping of the published amounts: the lower band collects the recurring class I / A-class IVD vigilance fee and the free-sale certificate available to a manufacturer of any class; the upper band collects the recurring IIa/IIb/III vigilance fee and the class-independent expert charges (EUR 528.60 for placing a non-CE-marked device on the market, EUR 900 and EUR 1,500 for clinical-investigation documentation, EUR 1,200 for a cost-effectiveness expertise and EUR 2,000 for a classification and clinical-evaluation consultation). The radiation state fees sit on a separate, non-risk-class axis and are outside both bands.
  • Footnote 1 to the schedule's annex states that value added tax is not applied, under section 3(8) of the Value Added Tax Law, so every amount in this record is net of VAT.
  • The schedule was adopted on 18 December 2024 and took effect on 1 January 2025; the medical-device lines read here are items 8.1, 54, 55, 56, 57, 61, 62.1, 62.2 and 63 of the annex, and no device line was found in the schedule that is not published in this record.
  • The radiation state fees are the amounts in § 63 of Cabinet Regulation No. 65: EUR 97 for a registration certificate, EUR 170 for a licence, EUR 54 for changes to a registration certificate, EUR 84 for amendments to a licence and EUR 10 for the changes listed in § 64. They are payable before the application is submitted.
Last Updated

2026-09-16

Verification Status

official-verified

Official Sources
  • Title

    Zāļu valsts aģentūras maksas pakalpojumu cenrādis (Cabinet Regulation No. 895 of 18.12.2024, in force 01.01.2025; Latvijas Vēstnesis 249, 20.12.2024) — the medical-device items 8.1, 54, 55, 56, 57, 61, 62.1, 62.2 and 63 of the annex

    Url

    https://likumi.lv/ta/id/357532-zalu-valsts-agenturas-maksas-pakalpojumu-cenradis

    Effective Date

    2025-01-01

    Accessed Date

    2026-09-16

  • Title

    Darbību ar jonizējošā starojuma avotiem paziņošanas, reģistrēšanas un licencēšanas noteikumi (Cabinet Regulation No. 65 of 28.01.2021, in force 01.02.2021) — § 63 state fees for the radiation registration certificate and licence

    Url

    https://likumi.lv/ta/id/320612-darbibu-ar-jonizejosa-starojuma-avotiem-pazinosanas-registresanas-un-licencesanas-noteikumi

    Effective Date

    2021-02-01

    Accessed Date

    2026-09-16

Reviewed On

2026-09-16

Amount Status

exact-current

Range Available

Yes

Additional certifications and licences · 1 record
Open Latvia certifications →
Slug

latvia

Market

Latvia

Confidence

high

Schemes
  • Id

    lvd-medical-exclusion-mdr-electrical-safety

    Name

    Low Voltage Directive exclusion for medical electrical equipment — electrical safety carried inside MDR conformity assessment

    Category

    Medical Electrical Safety

    Status

    Included In Medical Registration

    Object

    Electrical Medical Equipment

    Note

    Annex II of Directive 2014/35/EU places electrical equipment for radiology and medical purposes outside the Low Voltage Directive, so no separate Latvian electrical-safety certificate exists for a medical device; electrical safety is assessed inside the MDR conformity assessment against MDR Annex I, with the harmonised IEC/EN 60601 series carrying the presumption of conformity. The Latvian instrument transposing the Low Voltage Directive for standalone equipment was not retrieved, so this row is bound to the Union directive.

    Source Urls
    • https://eur-lex.europa.eu/eli/dir/2014/35/oj
    Source Binding

    candidate

  • Id

    emc-directive-disapplied-by-mdr

    Name

    EMC Directive disapplied where MDR fixes the same essential requirements

    Category

    emc

    Status

    Included In Medical Registration

    Object

    Electrical Medical Equipment

    Note

    Article 2(3) of Directive 2014/30/EU switches the EMC Directive off where other Union legislation lays the same essential requirements down more specifically, which MDR Annex I sections 18.5 and 18.6 do for medical devices. EMC is therefore dossier evidence inside the CE route rather than a separate Latvian conformity step; where a device is also radio equipment, § 1.1 of Cabinet Regulation No. 215 brings it within the Latvian radio-equipment conformity-assessment and surveillance regime. The Latvian instrument transposing the EMC Directive for standalone equipment was not retrieved, so this row is bound to the Union directive.

    Source Urls
    • https://eur-lex.europa.eu/eli/dir/2014/30/oj
    Source Binding

    candidate

  • Id

    ptac-radio-equipment-market-surveillance

    Name

    Radio-equipment essential requirements, conformity assessment and market surveillance (Cabinet Regulation No. 215)

    Category

    Radio Spectrum

    Status

    Mandatory If Feature

    Object

    Radio Equipment

    Note

    Radioiekārtu atbilstības novērtēšanas, piedāvāšanas tirgū, uzstādīšanas, lietošanas un uzraudzības noteikumi, Cabinet Regulation No. 215 of 02.04.2024, in force 11.04.2024, is made under Article 7 of the law 'Par atbildības novērtēšanu' and Article 33(2) of the Electronic Communications Law. It states the requirements for placing radio equipment on the market, for its installation and use, the market-surveillance procedure and the conformity-assessment procedure. § 2 provides verbatim that 'Radioiekārtu tirgus uzraudzību veic Patērētāju tiesību aizsardzības centrs, kas šo noteikumu izpratnē ir tirgus uzraudzības iestāde', and § 3, as amended by Cabinet Regulation No. 733 of 09.12.2025, that 'Radioiekārtu lietošanas uzraudzību veic sabiedrība ar ierobežotu atbildību "Elektroniskie sakari", kas šo noteikumu izpratnē ir lietošanas uzraudzības institūcija'. A medical device that is also radio equipment therefore carries these requirements in addition to the MDR route. The Latvian radio-equipment market-surveillance authority is PTAC, not the electronic-communications regulator and not the health inspectorate.

    Source Urls
    • https://likumi.lv/ta/id/351106-radioiekartu-atbilstibas-novertesanas-piedavasanas-tirgu-uzstadisanas-lietosanas-un-uzraudzibas-noteikumi
    Source Binding

    reviewed

  • Id

    ptac-legal-metrology-supervision

    Name

    State metrological supervision, type approval and verification of measuring instruments (PTAC)

    Category

    Legal Metrology

    Status

    Mandatory If Feature

    Object

    Legal Measuring Instruments

    Note

    Under the law 'Par mērījumu vienotību' of 27.02.1997 the state metrological control of measuring instruments consists of conformity assessment or type approval together with initial verification, the repeated verification of instruments in use, and state metrological supervision, which PTAC's own page states verbatim is 'valsts metroloģiskā uzraudzība, kuru pilnvarots veikt Patērētāju tiesību aizsardzības centrs'. Cabinet Regulation No. 289 of 14.05.2024, in force 15.07.2024, made under Article 7(2) of that law, sets the list of measuring instruments subject to state metrological control together with their initial verification and the periodicity of repeated verification. A medical device that is a legal measuring instrument (for example a sphygmomanometer or a clinical thermometer used in a regulated measurement) therefore carries its own Latvian metrological duty; the CE marking on a medical device does not discharge it. No Latvian fee amount for type approval or verification was retrieved.

    Source Urls
    • https://likumi.lv/ta/id/351985-noteikumi-par-valsts-metrologiskajai-kontrolei-paklauto-merisanas-lidzeklu-sarakstu
    • https://www.ptac.gov.lv/lv/reglamenteta-metrologija
    Source Binding

    reviewed

  • Id

    vvd-radiation-safety-centre-licensing

    Name

    Notification, registration certificate or licence for activities with ionizing radiation sources (VVD Radiation Safety Centre)

    Category

    Ionizing Radiation

    Status

    Mandatory For Use Site

    Object

    Ionizing Radiation Sources And Equipment

    Note

    Darbību ar jonizējošā starojuma avotiem paziņošanas, reģistrēšanas un licencēšanas noteikumi, Cabinet Regulation No. 65 of 28.01.2021, in force 01.02.2021, is made under Article 5(12), Article 11(4) and (7), Article 12(2) and Article 13 of the law 'Par radiācijas drošību un kodoldrošību'. It splits activities with ionizing radiation sources into notifiable, registrable and licensable activities and requires the operator to hold whichever instrument its activity falls under. § 13.3 names the competent body verbatim as 'Valsts vides dienesta Radiācijas drošības centrs (turpmāk – centrs)'. § 62 requires the state fee to be paid before the application is submitted, by bank transfer or through the payment module in the State Environmental Service information system, and § 63 fixes the amounts: EUR 97 for a registration certificate, EUR 170 for a licence, EUR 54 for changes to a registration certificate, EUR 84 for amendments to a licence and EUR 10 for the changes listed in § 64. A medical device that produces ionizing radiation (an X-ray unit, a CT scanner, an accelerator) is in scope at the site where it is used, in addition to the MDR route and the device's own CE marking.

    Source Urls
    • https://likumi.lv/ta/id/320612-darbibu-ar-jonizejosa-starojuma-avotiem-pazinosanas-registresanas-un-licencesanas-noteikumi
    Source Binding

    reviewed

  • Id

    mk331-eee-and-battery-producer-register

    Name

    Producer registration for electrical and electronic equipment and for batteries, and the annual data-maintenance payment

    Category

    Environmental And Batteries

    Status

    Mandatory Pre Market

    Object

    Electrical And Electronic Equipment And Batteries

    Note

    Elektrisko un elektronisko iekārtu un bateriju vai akumulatoru ražotāju reģistrācijas kārtība un samaksas kārtība par datu uzturēšanu, Cabinet Regulation No. 331 of 17.06.2014, in force 01.07.2014 (as amended by Cabinet Regulation No. 227 of 28.04.2026), is made under Article 24(2) and (4) and Article 31(3) and (4) of the Waste Management Law. § 7 requires a producer of electrical and electronic equipment to submit a registration application (Annex 1) to the registrar together with a document evidencing the advance payment referred to in § 37.1, and to be registered in the equipment producer register, which the registrar maintains; § 7.1 imposes the same on an authorised representative of a foreign producer within one month of being authorised; § 8 requires the documents for each foreign producer represented and a separate payment for each. § 22 requires a producer of batteries to submit a registration application (Annex 1.2) together with the advance payment referred to in § 37.2, the authorised representative's route being in § 23, framed by Article 56(3) of Regulation (EU) 2023/1542. The duty is therefore a producer obligation attaching to placing electrical and electronic equipment and batteries on the Latvian market. The data-maintenance payment is fixed in § 37: EUR 42.69 on registration and EUR 42.69 for each subsequent calendar year for equipment producers (§ 37.1) and the same amounts for battery producers (§ 37.2).

    Source Urls
    • https://likumi.lv/ta/id/267141
    Source Binding

    reviewed

Official Sources
  • Authority

    Latvijas Vēstnesis (likumi.lv)

    Topic

    Radioiekārtu atbilstības novērtēšanas, piedāvāšanas tirgū, uzstādīšanas, lietošanas un uzraudzības noteikumi (Cabinet Regulation No. 215 of 02.04.2024, in force 11.04.2024) — § 2 market-surveillance authority, § 3 use-surveillance body

    Url

    https://likumi.lv/ta/id/351106-radioiekartu-atbilstibas-novertesanas-piedavasanas-tirgu-uzstadisanas-lietosanas-un-uzraudzibas-noteikumi

  • Authority

    Latvijas Vēstnesis (likumi.lv)

    Topic

    Noteikumi par valsts metroloģiskajai kontrolei pakļauto mērīšanas līdzekļu sarakstu (Cabinet Regulation No. 289 of 14.05.2024, in force 15.07.2024)

    Url

    https://likumi.lv/ta/id/351985-noteikumi-par-valsts-metrologiskajai-kontrolei-paklauto-merisanas-lidzeklu-sarakstu

  • Authority

    Patērētāju tiesību aizsardzības centrs (PTAC)

    Topic

    Reglamentētā metroloģija — state metrological supervision, type approval and verification under the law 'Par mērījumu vienotību'

    Url

    https://www.ptac.gov.lv/lv/reglamenteta-metrologija

  • Authority

    Latvijas Vēstnesis (likumi.lv)

    Topic

    Darbību ar jonizējošā starojuma avotiem paziņošanas, reģistrēšanas un licencēšanas noteikumi (Cabinet Regulation No. 65 of 28.01.2021, in force 01.02.2021) — radiation registration certificate and licence, and the § 63 state fees

    Url

    https://likumi.lv/ta/id/320612-darbibu-ar-jonizejosa-starojuma-avotiem-pazinosanas-registresanas-un-licencesanas-noteikumi

  • Authority

    Latvijas Vēstnesis (likumi.lv)

    Topic

    Elektrisko un elektronisko iekārtu un bateriju vai akumulatoru ražotāju reģistrācijas kārtība un samaksas kārtība par datu uzturēšanu (Cabinet Regulation No. 331 of 17.06.2014, in force 01.07.2014)

    Url

    https://likumi.lv/ta/id/267141

  • Authority

    EUR-Lex

    Topic

    Directive 2014/35/EU (Low Voltage Directive), Annex II — electrical equipment for radiology and medical purposes excluded

    Url

    https://eur-lex.europa.eu/eli/dir/2014/35/oj

  • Authority

    EUR-Lex

    Topic

    Directive 2014/30/EU (EMC Directive), Article 2(3)

    Url

    https://eur-lex.europa.eu/eli/dir/2014/30/oj

Keep researching this market

More Latvia medical device resources

View the Latvia resource hub →
Continue with this market
DJ Fang
Need to apply Latvia's requirements to a product?
Confirm the current ZVA pathway, evidence, and local-role details for the actual device before filing.
Pricing